@IOBiotech today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Read the full press release here: bit.ly/3YPUOCS

🗨️ “This is the first time we have ever seen a vaccine lead to separation in PFS curves in the metastatic setting.” @IOBiotech vaccine ➕ @KEYTRUDA combo shows “impressive” activity in advanced #melanoma, Dr. Inge Marie Svane @CCITdk tells @GoHealio. bit.ly/473Py3h

IO Biotech presented detailed results from our global Phase 3 study of investigational Cylembio® (imsapepimut and etimupepimut, adjuvanted) plus KEYTRUDA® (pembrolizumab) for the treatment of advanced melanoma at the ESMO 2025 Congress in Berlin. Read the full press release here: bit.ly/4qrb21R #IOBiotech #CancerResearch #ESMO2025

What do you recommend now with my stocks?

What a disaster.

@IOBiotech is pleased to announce that Mai-Britt Zocca, PhD, President & CEO, will serve on the ‘Keeping Hope Alive: Learnings on How Pre-POC Oncology Biotechs Can Successfully Navigate Current Challenging Times’ virtual panel as part of Lumanity’s Cancer Progress Webinar taking place on September 10, 10:30 AM – 12:00 PM ET. Dr. Zocca will share her perspective on what it has taken over the past decade to successfully bring an investigational immune-modulatory therapeutic cancer vaccine from proof-of-concept through a pivotal Phase 3 clinical trial. Learn more and register for the event here: bit.ly/42kxUW5

Cylembio Plus Keytruda Extends PFS in Trial For Advanced Melanoma @IOBiotech #Melanoma #Oncology curetoday.com/view/phase-3-t…

nice interview! @US_FDA should definitely consider an accelerated approval.

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: @IOBiotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead. $IOBT Full video: biotechtv.com/post/io-biotec…

𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰: We will discuss with the Founder & CEO of @IOBiotech what is next after this week's trial result in advanced melanoma. $IOBT

Interested in learning more about investigational immune-modulatory therapeutic cancer vaccines and their potential to treat a wide range of cancers? @IOBiotech team members are presenting posters at the #AACR25 Annual Meeting on Monday, April 28. Stop by and meet our colleagues to learn more: Marion Chapellier, PhD, will present new data supporting the dual mechanism of action of our lead immune-modulatory, off-the-shelf therapeutic cancer vaccine candidate, IO102-IO103, which targets cells that express IDO1 and PD-L1 to control tumor growth. Justin Joseph, PhD, will be sharing new preclinical data for the third candidate in our pipeline, IO170, which targets transforming growth factor beta (TGF-beta). We hope to see you there!

We invest €57.5m in @IOBiotech to advance its investigational immune-modulatory, off-the-shelf therapeutic cancer vaccine for melanoma. This will support clinical development, approval & market launch, strengthening Denmark’s med-tech sector⤵️ bit.ly/Biotech_Denmark #InvestEU

💡 Tech Update 🧬 undervalued #IOBiotech ranked #9 most innovative biotech for #cancer vaccines 🔬 #Microsoft partners #Inait for brain-inspired #AI 💾 #Nvidia unveils #Llama Nemotron — open-source AI for enterprise 🧠 #LG launches #EXAONE Deep — AI rivaling #DeepSeek V1 🚘 #Lyft plans #AV launch this summer 🔋 #BYD launches Battery-Box HVE — first home energy system 🤖 Nvidia CEO: #Humanoidrobots in factories within 5 years 💸 #SoftBank buys #Ampere Computing for $6.5B 📡 #Vocus gets green light to buy #TPG 💻 #CoreWeave targets ~$2.5B #IPO 🏗️ #Northwestern develops carbon-negative building tech 🎥 #Disney shareholders reject anti-DEI proposal #Tech #News #Markets #Equities #Biotech #DEI #Carboncapture #Energysystem #Fastcompany

We are honored to be recognized by @FastCompany for our leadership in the biotech industry with the development of our potentially game-changing approach to immune-modulatory cancer vaccines. Many thanks to all of our employees, founders, scientific advisors, and investors who share our mission of changing the immuno-oncology treatment paradigm and have made this honor possible! #FCMostInnovative #Innovation #IOBiotech

Exciting News! We’re thrilled to be named #9 in the world in Biotech on Fast Company’s Most Innovative Companies of 2025 list! This notable distinction reflects @IOBiotech's relentless pursuit of pioneering off-the-shelf cancer vaccines that have the potential to change the oncology treatment paradigm with a product candidate that is designed to be available when a patient receives their diagnosis. Recognized for our innovative, T-win® platform, our broadly applicable investigational therapeutic cancer vaccines are designed to target and kill both tumor cells and immune-suppressive cells in the tumor microenvironment, and lead to improved patient outcomes. A heartfelt thank you to @FastCompany for this distinction and to our dedicated team, partners, and supporters who make this mission possible every day. Read the full press release here: bit.ly/41D4yBr #fcmostinnovative #Innovation #IOBiotech

We are proud to be a gold sponsor of the @MelanomaReAlli 2025 Scientific Retreat. Join members of our @IOBiotech team including our President & CEO, Mai-Britt Zocca, PhD, and our CMO, Qasim Ahmad, MD, at this year's MRA Scientific Retreat, which is the premier annual convening of global thought leaders from across the melanoma research community. We look forward to engaging discussions and collaboration with fellow researchers and experts in the oncology field worldwide, all focused on making a difference in melanoma. We hope to see you there! Visit our website: iobiotech.com/

Vaccines making a comeback , strong and able. We have dedicated our #clinicaltrials program to success together in multiple solid tumors @angeles - @moderna_tx @IOBiotech @BioNTech_Group working in the #adjuvant , #metastatic and #neoadjuvant onclive.com/view/dr-hamid-on…

As we celebrate our 10-year anniversary, we look back at some of the milestones that helped shape our company. We know that the past decade is only the first step, and we are excited about what the next ten years will bring for @IOBiotech as we look forward to the Phase 3 trial pivotal read out for our lead investigational therapeutic cancer vaccine. Take a look at some of our team’s proudest moments over the past ten years. Happy Anniversary IO Biotech! #IOBT; #cancervaccine; #ignitechangebreakboundaries

IO Biotech: Combo IO102-IO103 KEYTRUDA Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study $IOBT, #IOBiotech, $MRK, #Merck, #MSD crweworld.com/article/news-p…

𝐅𝐫𝐨𝐦 𝐂𝐨𝐩𝐞𝐧𝐡𝐚𝐠𝐞𝐧: @IOBiotech is developing a cancer vaccine that targets both the tumor and its microenvironment. A pivotal trial readout is coming in the first half of next year. Full video: biotechtv.com/post/io-biotec…